Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314985 | 0.87 | PIK3CD (0.48) | CYP2D6CACNA1BPIK3CD | |
| SCHEMBL31158094 | 0.82 | CYP2D6 (0.51) | CYP2D6CACNA1BPIK3CD | |
| SCHEMBL20034180 | 0.78 | PIK3CD (0.46) | PIK3CD | |
| SCHEMBL20334556 | 0.78 | CYP2D6 (0.48) | CYP2D6CACNA1BPIK3CD | |
| SCHEMBL21794520 | 0.76 | CYP2D6 (0.53) | CYP2D6CACNA1BPIK3CD | |
| SCHEMBL20314942 | 0.72 | CYP2D6 (0.37) | CYP2D6CACNA1BPIK3CD | |
| SCHEMBL10283831 | 0.69 | BLM (0.47) | PIK3CD | |
| SCHEMBL20334577 | 0.69 | CYP2D6 (0.39) | CYP2D6CACNA1B | |
| SCHEMBL20314986 | 0.67 | ALDH1A1 (0.38) | CYP2D6 | |
| SCHEMBL2028346 | 0.65 | TDP1 (0.48) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CYP2D6 4615/4885CACNA1B 4285/4885PIK3CD 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.